Our recent activity

ANACONDA BIOMED S.L. secures €20 Million round of funding

Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has closed €20 million in new funding. The funding will be used for clinical studies of the company’s groundbreaking technology, regulatory submissions in international markets, further product development and manufacturing scale-up.

“With this new round of funding, we will be able to advance our work in developing and testing next-generation technology that has the potential to dramatically accelerate and improve endovascular treatment of major ischemic stroke patients,” stated Francois Salmon, CEO of Anaconda Biomed S.L.. “This financial backing is further validation that the lifesaving work we are engaged in at Anaconda is absolutely vital in the quest to reduce the incidence of death and disability following a stroke.”

Finding new and more effective treatments for the onset of stroke remains a medical priority for the healthcare industry. According to the Lancet, stroke is the second leading cause of death worldwide with 5.5 million deaths attributed to this cause in 2016. A New England Journal of Medicine report from the Global Burden of Disease (GBD) 2016 Lifetime Risk of Stroke Collaborators stated that the estimated global lifetime risk of stroke in 2016 for those aged 25 years or older was 24.9 percent, an increase from 22.8 percent in 1990.

Barcelona, Spain-based venture capital firm Asabys Partners led the round from its fund, Sabadell Asabys Health Innovation Investments SCR, SA, with participation from existing investors Ysios CapitalOmega Funds and Innogest, as well as Sabadell Venture Capital, who joined the previous financing round.

“For Asabys Partners, this investment in Anaconda is a confirmation of our investment strategy, which is focused on pushing the boundaries of science and technology with the goal of addressing some of today’s most challenging medical issues,” said Josep Ll. Sanfeliu, co-founder of Asabys Partners.

Sylvain Sachot, investment director of Asabys Partners, added, “We believe that Anaconda will bring a cutting-edge thrombectomy system to the market that will effectively treat one of the leading causes of death and incapacity in the world today.”

Anaconda’s Advanced Thrombectomy System consists of a delivery catheter, a unique, funnel-shaped aspiration catheter and a stent retriever. When deployed, the funnel self-expands and directly conforms to the artery diameter up to 5mm, locally arresting flow and allowing full thrombus extraction without fragmentation. The system is designed to deliver significant improvement in revascularization rates at both first and third pass.

Anaconda Biomed S.L. has already enrolled 14 patients in a 125-patient first-in-human study with results to be used to support a regulatory submission to the U.S. Food and Drug Administration.

About Asabys Partners

Sabadell Asabys Health Innovation Investments SCR, SA is a venture capital vehicle managed by Asabys Partners, a firm founded by Josep Ll. Sanfeliu and Clara Campàs. Sabadell Asabys Health Innovation Investments is backed by Banc Sabadell as anchor investor and has a target size of over 80 million euros, aiming to invest in 12 companies in the next years.

Asabys was founded in 2018 and started operations in 2019. Asabys is focused on medtech, digital therapeutics, and early stage biopharma, supporting highly innovative and transformative technologies.Since its inception, Asabys Partners has invested in Psious, a digital mental health company, also invested in the early stage biotech company Ona Therapeutics, and recently in the Berlin-based digital therapeutics company, Care Care, in the area of gastrointestinal diseases in co-investment with Johnson & Johnson. For more information, visit www.asabys.com.

About Anaconda Biomed S.L.

Anaconda Biomed S.L. is a medical technology company dedicated to developing next generation thrombectomy systems for the treatment of ischemic stroke. Its flagship product is the Advanced Thrombectomy System. For more information, visit https://anaconda.bio/.


Joe Duraes

Nobles Global Communications



September 8, 2021

#EntrevistaBiospain2021 | Asabys, el primer inversor de salud español acreditado por su compromiso con los Objetivos de Desarrollo Sostenible

Hablamos con Clara Campàs y Josep Lluís Sanfeliu, fundadores del fondo de capital riesgo Asabys Partners, Silver Sponsor de Biospain 2021, sobre su compromiso con la sostenibilidad y el futuro…
July 8, 2021

Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies

READ THIS NEWS IN SPANISH Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases Joint development agreement represents a promising step towards a…
Asabys Partners and Bureau VeritasInternal
May 13, 2021

Asabys Partners certifies with Bureau Veritas its Social Responsibility Management System aligned with the Sustainable Development Goals (SDGs) from United Nations

Asabys Partners, venture capital firm investing in innovative companies within the healthcare space, announces today the certification of its management system of CSR aligned with the Sustainable Development Goals from…

Leave a Reply